Surrozen Inc (SRZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surrozen Inc (SRZN) has a cash flow conversion efficiency ratio of 0.384x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.04 Million) by net assets ($-23.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Surrozen Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Surrozen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Surrozen Inc carry for a breakdown of total debt and financial obligations.
Surrozen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surrozen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polytronics Technology Corp
TW:6224
|
0.010x |
|
InfuSystems Holdings Inc
NYSE MKT:INFU
|
0.124x |
|
Tribune Resources Ltd
AU:TBR
|
0.081x |
|
Arise Windpower AB
ST:ARISE
|
0.147x |
|
Embention Sistemas Inteligentes S.A.
PA:MLUAV
|
N/A |
|
First Hotel Co Ltd
TW:2706
|
0.005x |
|
Stove Kraft Limited
NSE:STOVEKRAFT
|
0.052x |
|
Maiquer Group Co Ltd
SHE:002719
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Surrozen Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Surrozen Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SRZN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-21.38 Million | $-17.63 Million | 0.825x | +177.49% |
| 2023-12-31 | $37.94 Million | $-40.36 Million | -1.064x | -83.18% |
| 2022-12-31 | $76.00 Million | $-44.15 Million | -0.581x | -30.54% |
| 2021-12-31 | $109.70 Million | $-48.81 Million | -0.445x | +27.68% |
| 2020-12-31 | $47.29 Million | $-29.10 Million | -0.615x | +14.13% |
| 2019-12-31 | $29.39 Million | $-21.06 Million | -0.717x | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which co… Read more